RhuDex is under clinical development by MediGene and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RhuDex’s likelihood of approval (LoA) and phase transition for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) took place on 14 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RhuDex Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RhuDex is under development for the treatment of primary biliary cholangitis. It is administered through oral route. RhuDex is a small molecule which acts by targeting CD80. It was also under development for the treatment of autoimmune disorders such as rheumatoid arthritis (RA)
MediGene is a biotechnology company which develops innovative immunotherapies to treat cancer with candidates in clinical and pre-clinical development. It focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), for isolation of antibodies for monitoring and tracking of TCR-Ts. The company has operational presence in the US and Europe. MediGene is headquartered in Planegg, Germany.
Quick View RhuDex LOA Data
|Highest Development Stage|